Where the brain's electrical language becomes a treatment protocol.
For patients whose conditions resist every name, we measure what other clinics cannot yet see — and build a path from that signal.
Patients enrolled in active studies
Diagnostic concordance rate
Novel biomarkers identified since 2019
The corridor begins with one question: have other clinics stopped asking?
We accept patients through neurologist referral or direct self-referral. If your child has had three seizure medications fail, or your post-stroke plateau has lasted longer than the recovery window anyone quoted you — this intake is where that changes.
Our intake coordinators review every submission within three business days. You will receive either a screening call or a clear explanation of why this pathway may not be the right fit at this time. We do not maintain indefinite waitlists.
Four simultaneous imaging modalities. One integrated signal map.
Standard clinical EEG captures 30 minutes of activity on 21 electrodes. Our protocol runs 256-channel high-density EEG alongside fMRI, MEG, and metabolic PET — simultaneously, over multiple sessions — building a signal portrait that single-modality imaging cannot produce.
Sessions are designed around patient comfort. Sedation is available for pediatric patients. Remote telemetry options exist for monitoring phases following in-person baseline acquisition.
Six patterns no clinical lab currently tests for. Each one a map coordinate.
Since 2019, our analysis pipeline has identified six biomarkers absent from standard diagnostic panels — patterns in how neural signals couple, suppress, and propagate that correlate with specific treatment response profiles. These are not experimental guesses; each has published concordance data.
Biomarker analysis results are reviewed by a panel of three neurophysiologists before any protocol recommendation is generated. Families receive a written report in plain language alongside the technical summary.
Your signal profile opens doors that general referrals cannot.
Biomarker findings are cross-referenced against our active trial registry and partner institution studies. Patients who match a trial profile receive a structured briefing — what the trial measures, what participation requires, what the exit criteria are — before any enrollment decision.
Participation in trials is always voluntary. Patients who do not match any active trial are not discharged from care; they enter our longitudinal monitoring cohort and are flagged automatically when new trials open.
The signal doesn't stop changing. Neither does the protocol.
Enrollment in longitudinal monitoring means your neural signal data is reviewed at 3, 6, 12, and 24-month intervals. Treatment protocols are adjusted based on signal drift — the small shifts in biomarker expression that precede both improvement and relapse.
Our 24-month outcome cohort shows a median 82% reduction in seizure frequency for enrolled patients. Post-stroke patients in the aphasia protocol show meaningful language recovery at 18 months in 71% of cases — compared to 34% in matched clinical controls.
Clarity is possible. We can help you find it.
If your condition has resisted three opinions, two medication trials, or a year without answers — the work here is designed for exactly that uncertainty.
No obligation. Screening takes approximately 8 minutes.